The U.S. is having its worst year for measles in more than three decades
The U.S. Centers for Disease Control and Prevention (CDC) said Wednesday that the national case count surpassed 2019, when there were 1,274 cases for the year and the country almost lost its status of having eliminated the vaccine-preventable illness. That could happen this year if the virus has nonstop spread for 12 months.
This year's outbreaks, some of them interconnected, started five months ago in undervaccinated communities in West Texas. Three people have died — two children in Texas and an adult in New Mexico — and dozens of people have been hospitalized. Public health experts maintain the true case count may be higher than state health departments have confirmed.
North America has three other major measles outbreaks, with 2,966 cases in Chihuahua state, Mexico, 2,223 cases in Ontario and 1,230 in Alberta. Thirteen other states have current confirmed outbreaks of three or more people — Arizona, Colorado, Georgia, Illinois, Iowa, Kansas, Michigan, Missouri, Montana, New Mexico, North Dakota, Oklahoma and Utah — and four other states saw their outbreaks end.
The measles, mumps and rubella vaccine is 97% effective at preventing measles after two doses.
The World Health Organization said in 2000 that measles had been eliminated from the U.S.
The CDC identified 22 outbreaks in 2019, the largest being two separate clusters in New York — 412 in New York state and 702 in New York City. These were linked because as measles was spreading through close-knit Orthodox Jewish communities, the CDC said.
It's a similar situation in North America this year, where the Canada, Mexico and Texas outbreaks stem from large Mennonite communities in the regions. Mennonite churches do not formally discourage vaccination, though more conservative Mennonite communities historically have low vaccination rates and a distrust of government.
A recent study found childhood vaccination rates against measles fell after the COVID-19 pandemic in nearly 80% of the more than 2,000 U.S. counties with available data, including in states that are battling outbreaks this year.
Only 92.7% of kindergarteners in the U.S. had the measles, mumps and rubella vaccine in the 2023-2024 school year, below the 95% needed to prevent outbreaks. In Gaines County, Texas, the epicenter of the Texas outbreak, only 82% of kindergarteners were up-to-date with MMR vaccines.
State and federal leaders have for years kept funding stagnant for local public health departments' vaccination programs that are tasked with reversing the trend.
'What we're seeing with measles is a little bit of a 'canary in a coal mine,'' said Lauren Gardner, leader of Johns Hopkins University's independent measles and COVID tracking databases. 'It's indicative of a problem that we know exists with vaccination attitudes in this county and just, I think, likely to get worse.'
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Devi Shastri, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
Refractory Metastatic Melanoma Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Refractory Metastatic Melanoma Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Refractory Metastatic Melanoma Research. Learn more about our innovative pipeline today! @ Refractory Metastatic Melanoma Pipeline Outlook Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report In July 2025, Genmab announced clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. DelveInsight's Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Refractory Metastatic Melanoma treatment. The leading Refractory Metastatic Melanoma Companies such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Promising Refractory Metastatic Melanoma Pipeline Therapies such as GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Stay informed about the cutting-edge advancements in Refractory Metastatic Melanoma treatments. Download for updates and be a part of the revolution in Dermatology care @ Refractory Metastatic Melanoma Clinical Trials Assessment Refractory Metastatic Melanoma Emerging Drugs Profile BNT111: BioNTech SE BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with anti-PD-(L) 1 refractory/relapsed, unresectable Stage III or IV melanoma. BNT111 is an mRNA-based off-the-shelf cancer immunotherapy candidate for intravenous administration encoding a fixed set of four non-mutated melanoma-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) delivered as uridine mRNA-lipoplex formulation. Over 90% of patients with cutaneous melanomas express at least one of these antigens. The BNT111 program has also received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration. Currently, the drug is in Phase II stage of its development for the treatment of Refractory Metastatic Melanoma. GD2-SADA: Y-mAbs Therapeutics The GD2-SADA construct is created using SADA technology, that utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs attached to the tumor target in order to radiate the tumor. This provides the possibility of targeting tumors with precision while minimizing radiation of normal tissues. The SADA technology platform can deliver a variety of payloads and could potentially be developed against multiple tumor targets, as well as for theragnostic purposes. Currently, the drug is in Phase I stage of its development for the treatment of Refractory Metastatic Melanoma. The Refractory Metastatic Melanoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Metastatic Melanoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma Treatment. Refractory Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Refractory Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Metastatic Melanoma market. Learn more about Refractory Metastatic Melanoma Drugs opportunities in our groundbreaking Refractory Metastatic Melanoma research and development projects @ Refractory Metastatic Melanoma Unmet Needs Refractory Metastatic Melanoma Companies BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Refractory Metastatic Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of dermatology @ Refractory Metastatic Melanoma Market Drivers and Barriers, and Future Perspectives Scope of the Refractory Metastatic Melanoma Pipeline Report Coverage- Global Refractory Metastatic Melanoma Companies- BioNTech SE, Y-mAbs Therapeutics, Seagen Inc. and others. Refractory Metastatic Melanoma Pipeline Therapies- GIM-531, Acasunlimab, Pembrolizumab, GSK2118436, GSK1120212, BNT111, Cemiplimab, BA3071, Nivolumab and others. Refractory Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Refractory Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Refractory Metastatic Melanoma Pipeline on our website @ Refractory Metastatic Melanoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Refractory Metastatic Melanoma: Overview Pipeline Therapeutics Therapeutic Assessment Refractory Metastatic Melanoma – DelveInsight's Analytical Perspective In-depth Commercial Assessment Refractory Metastatic Melanoma Collaboration Deals Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) BNT111: BioNTech SE Drug profiles in the detailed report….. Early Stage Products (Phase I) GD2-SADA: Y-mAbs Therapeutics Drug profiles in the detailed report… Pre-clinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Refractory Metastatic Melanoma Key Companies Refractory Metastatic Melanoma Key Products Refractory Metastatic Melanoma- Unmet Needs Refractory Metastatic Melanoma- Market Drivers and Barriers Refractory Metastatic Melanoma- Future Perspectives and Conclusion Refractory Metastatic Melanoma Analyst Views Refractory Metastatic Melanoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CBC
5 hours ago
- CBC
Some Alberta hospitals triaging probable measles patients in vehicles
Some Alberta hospitals are triaging probable measles patients in their vehicles, as the province's outbreak continues to grow. Harkening back to the COVID-19 days, patients showing up at the Grey Nuns Community Hospital in south Edmonton with measles symptoms are now being triaged in the ambulance bay rather than waiting for isolation rooms. Janet Laurie, a spokesperson for Covenant Health, said in an email that it expedites the process and ensures patients receive the care they need. She added that the process was in place in many other sites in Alberta. Dr. Stephanie Smith, an infectious disease specialist at the University of Alberta Hospital, said the triage system being used adds an "extra layer of caution" that also protects other patients in the emergency department. She said the system has been in place for at least the past couple of months, especially in facilities like the Stollery Children's Hospital, where young children cannot be fully vaccinated. Of Edmonton's total 12 measles cases since March, three were detected at the Grey Nuns. "This is of great concern given how contagious measles is and the risk to children under five and patients who are immunocompromised," Laurie said. "An outbreak on a unit would close it down to further admissions and place additional stress on the system." A spokesperson for Alberta Health Services said the process is used at health-care facilities but it is not used often. "It is used as needed and has been in place intermittently since March, so it is not a new measure," said Kristi Bland in an email. "It is not a response to a significant increase in cases, nor does it reflect an unreported or emerging number of cases." 'Dangerous territory' Former Alberta chief medical officer of health Dr. James Talbot weighed in as the province's caseload hit 1,246 Wednesday. "It says we're in dangerous territory," said Talbot, an adjunct professor at the University of Alberta's School of Public Health. "What physicians and public health experts have been saying for months now is that the province has been very slow to react to this." "We now have the worst record in North America." Talbot said he is worried growing outbreaks could lead to the country losing its measles-free status. Being stripped of the status achieved in 1998 could have both reputational and economic impacts for Canada, he said. "If the control measures are in place and used properly and properly resourced, we didn't have to get there and we still have the ability to get back to where there aren't any measles," Talbot said. "But the longer it lasts, the more people affected, the more costly it's going to be, the longer it's going to take to get back to zero." Vaccination rates up: province Maddison McKee, press Secretary to Minister of Primary and Preventative Health Services Adriana LaGrange, said vaccination efforts are making a difference, including the addition of clinics and extended hours. She said during an ongoing multi-lingual immunization campaign launched in May, Alberta saw immunizations increase by more than 65 per cent compared to the same time last year. "Between March 16 and June 28, more than 75,000 measles vaccines were administered across Alberta—an increase of more than 57 per cent compared with the same period last year. In the South Zone alone, vaccine uptake rose by 126 per cent," McKee wrote. She pointed out that there have been no new cases in Edmonton since March and none that are currently active. Talbot said he wants to see regular updates from Alberta's chief medical officer of health alongside a more robust marketing campaign because of the possibility of exposures over the summer at events like baseball tournaments, summer camps and family gatherings. "That's potential for spread to other provinces," Talbot said. "And then come the fall, we'll see those kids return and go into school. And so then we'll have another wave that we have to worry about."
CTV News
6 hours ago
- CTV News
The biggest gender-affirming care center for trans kids in the US is closing, prompting protests
Protesters chant slogans while demonstrating against the closure of the trans youth clinic at Children's Hospital Los Angeles, Thursday, July 3, 2025, in Los Angeles. (AP Photo/Jae C. Hong) LOS ANGELES — Growing up, Sage Sol Pitchenik wanted to hide. 'I hated my body,' the nonbinary 16-year-old said. 'I hated looking at it.' When therapy didn't help, Pitchenik, who uses the pronoun they, started going to the Center for Transyouth Health and Development at Children's Hospital Los Angeles, the country's biggest public provider of gender-affirming care for children and teens. It changed their life. But in response to the Trump administration's threat to cut federal funds to places that offer gender-affirming care to minors, the center will be closing its doors July 22. Pitchenik has been among the scores of protesters who have demonstrated regularly outside the hospital to keep it open. 'Trans kids are done being quiet. Trans kids are done being polite, and trans kids are done begging for the bare minimum, begging for the chance to grow up, to have a future, to be loved by others when sometimes we can't even love ourselves,' Pitchenik said, prompting cheers from dozens of protesters during a recent demonstration. They went to the center for six years. 'There's a lot of bigotry and just hate all around, and having somebody who is trained specifically to speak with you, because there's not a lot of people that know what it's like, it meant the world,' they told The Associated Press. The center's legacy In operation for three decades, the facility is among the longest-running trans youth centers in the country and has served thousands of young people on public insurance. Patients who haven't gone through puberty yet receive counseling, which continues throughout the care process. For some patients, the next step is puberty blockers; for others, it's also hormone replacement therapy. Surgeries are rarely offered to minors. 'I'm one of the lucky ones,' said Pitchenik, who received hormone blockers after a lengthy process. 'I learned how to not only survive but how to thrive in my own body because of the lifesaving health care provided to me right here at Children's Hospital Los Angeles.' Many families are now scrambling to find care among a patchwork of private and public providers that are already stretched thin. It's not just patient care, but research development that's ending. 'It is a disappointment to see this abrupt closure disrupting the care that trans youth receive. But it's also a stain on their legacy,' said Maria Do, community mobilization manager at the Los Angeles LGBT Center. 'I think it showcases that they're quick to abandon our most vulnerable members.' The closure comes weeks after the Supreme Court upheld Tennessee's ban on gender-affirming care for minors, amid other efforts by the federal government to regulate the lives of transgender people. The hospital initially backed off its plans to close after announcing them in February, spurring demonstrations, but later doubled back. The center said in a statement that 'despite this deeply held commitment to supporting LA's gender-diverse community, the hospital has been left with no viable path forward' to stay open. 'Center team members were heartbroken to learn of the decision from hospital leaders, who emphasized that it was not made lightly, but followed a thorough legal and financial assessment of the increasingly severe impacts of recent administrative actions and proposed policies,' the statement said. California Attorney General Rob Bonta has warned that by closing the center, the hospital is violating state antidiscrimination laws, but his office hasn't taken any further action. Bonta and attorneys general from 22 other states sued President Donald Trump's administration over the executive order in February. 'The Trump administration's relentless assault on transgender adolescents is nothing short of an all-out war to strip away LGBTQ+ rights,' Bonta told the AP in an email. 'The Administration's harmful attacks are hurting California's transgender community by seeking to scare doctors and hospitals from providing nondiscriminatory healthcare. The bottom line is: This care remains legal in California.' LGBTQ+ protesters and health care workers offer visibility Still wearing scrubs, Jack Brenner joined protesters after a long shift as a nurse in the hospital's emergency room, addressing the crowd with a megaphone while choking back tears. 'Our visibility is so important for our youth,' Brenner said, looking out at a cluster of protesters raising signs and waving trans pride flags. 'To see that there is a future, and that there is a way to grow up and to be your authentic self.' Brenner, who uses the pronoun they, didn't see people who looked like them growing up or come to understand what being trans meant until their mid-20s. 'It's something I definitely didn't have a language for when I was a kid, and I didn't know what the source of my pain and suffering was, and now looking back, so many things are sliding into place,' Brenner said. 'I'm realizing how much gender dysphoria was a source of my pain.' Trans children and teens are at increased risk of suicidal thoughts and behaviors, according to a 2024 study from the Centers for Disease Control and Prevention. Brenner described encountering young patients in the emergency room who are trans or otherwise on the gender-nonconforming spectrum and 'at the peak of a mental health crisis.' Brenner wears a lanyard teeming with colorful pins emblazoned with the words 'they/them' to signal their gender identity. 'I see the change in kids' eyes, little glints of recognition, that I am a trans adult and that there is a future,' Brenner said. 'I've seen kids light up when they recognize something of themselves in me. And that is so meaningful that I can provide that.' Beth Hossfeld, a marriage and family therapist and a grandmother to an 11- and 13-year-old who received care at the center, called the closure 'patient abandonment.' 'It's a political decision, not a medical one, and that's disturbing to me,' she said. Anna Furman, The Associated Press
